[go: up one dir, main page]

TWI367098B - Treating agent for glaucoma - Google Patents

Treating agent for glaucoma

Info

Publication number
TWI367098B
TWI367098B TW094144075A TW94144075A TWI367098B TW I367098 B TWI367098 B TW I367098B TW 094144075 A TW094144075 A TW 094144075A TW 94144075 A TW94144075 A TW 94144075A TW I367098 B TWI367098 B TW I367098B
Authority
TW
Taiwan
Prior art keywords
glaucoma
treating agent
salt
preventing
intraocular pressure
Prior art date
Application number
TW094144075A
Other languages
English (en)
Other versions
TW200628160A (en
Inventor
Shin Sugimoto
Ken Mizuno
Masatoshi Takahashi
Makoto Kanebako
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of TW200628160A publication Critical patent/TW200628160A/zh
Application granted granted Critical
Publication of TWI367098B publication Critical patent/TWI367098B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW094144075A 2004-12-23 2005-12-13 Treating agent for glaucoma TWI367098B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63811804P 2004-12-23 2004-12-23

Publications (2)

Publication Number Publication Date
TW200628160A TW200628160A (en) 2006-08-16
TWI367098B true TWI367098B (en) 2012-07-01

Family

ID=36601805

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094144075A TWI367098B (en) 2004-12-23 2005-12-13 Treating agent for glaucoma

Country Status (23)

Country Link
EP (1) EP1818059B1 (zh)
JP (1) JP4099201B2 (zh)
KR (1) KR101286813B1 (zh)
CN (1) CN101087613B (zh)
AT (1) ATE415972T1 (zh)
AU (1) AU2005320085B2 (zh)
BR (1) BRPI0519007A2 (zh)
CA (1) CA2585372A1 (zh)
CY (1) CY1108651T1 (zh)
DE (1) DE602005011476D1 (zh)
DK (1) DK1818059T3 (zh)
EA (1) EA011085B1 (zh)
ES (1) ES2317338T3 (zh)
MX (1) MX2007007614A (zh)
MY (1) MY138811A (zh)
NO (1) NO20072187L (zh)
NZ (1) NZ555137A (zh)
PL (1) PL1818059T3 (zh)
PT (1) PT1818059E (zh)
SI (1) SI1818059T1 (zh)
TW (1) TWI367098B (zh)
WO (1) WO2006068208A1 (zh)
ZA (1) ZA200704874B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101223475B (zh) * 2005-07-14 2010-11-10 夏普株式会社 显示元件和使用该显示元件的电子设备
EP2319514A4 (en) 2008-07-25 2011-11-02 Asahi Kasei Pharma Corp STABLE AQUEOUS SOLUTION COMPOSITION COMPRISING A SULFONAMIDE COMPOUND
EP2671586B1 (en) * 2011-02-04 2018-05-30 Kowa Co., Ltd. Drug therapy for preventing or treating glaucoma
EA026904B1 (ru) * 2012-11-23 2017-05-31 Игорь Михайлович Юхт Способ количественного определения полигексаметиленбигуанидина (пгмб) гидрохлорида в составах для приготовления жидких лекарственных средств для лечения заболеваний глаз и носа (2 варианта)
EP3626245B1 (en) * 2013-04-24 2021-05-05 Kyushu University, National University Corporation Therapeutic agent for eyeground disease
JP6236167B2 (ja) * 2014-09-25 2017-11-22 興和株式会社 医薬品
PT3199160T (pt) * 2014-09-25 2020-04-08 Kowa Co Composição aquosa
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
CN107106571B (zh) 2014-12-12 2021-02-05 兴和株式会社 水性组合物
KR20160108121A (ko) 2015-03-06 2016-09-19 코와 가부시키가이샤 수성 조성물
JP2018118905A (ja) * 2015-04-27 2018-08-02 恵 本庄 白内障術後合併症の予防治療剤
CN106310285A (zh) * 2015-06-15 2017-01-11 江苏吉贝尔药业股份有限公司 一种新的盐酸利舒地尔滴眼液及其制备方法
JP6886322B2 (ja) * 2016-03-25 2021-06-16 興和株式会社 眼科用組成物
CN107164328A (zh) * 2017-06-30 2017-09-15 太仓卡斯特姆新材料有限公司 一种高稳定性mcf‑7乳腺癌细胞的复苏方法
WO2019124488A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
JP2020193174A (ja) * 2019-05-29 2020-12-03 興和株式会社 水性組成物
CA3207859A1 (en) 2021-01-11 2022-07-14 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9401108D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
DE19512639A1 (de) * 1995-04-05 1996-10-10 Merck Patent Gmbh Benzonitrile und -fluoride
AU720326B2 (en) * 1995-12-21 2000-05-25 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
JPH10310576A (ja) * 1997-03-10 1998-11-24 Hiroyoshi Hidaka イソキノリンスルフォンアミド誘導体及びこれを有効成分とする医薬
KR100390612B1 (ko) * 1997-04-25 2003-07-07 화이자 인코포레이티드 타입 5 시클릭 구아노신 3',5'-모노포스페이트포스포디에스테라제를 억제하는 성기능 장애 치료용피라졸로피리미디논 제조용 중간체의 제조 방법
FR2777189B1 (fr) 1998-04-09 2001-04-06 Chauvin Lab Sa Composition ophtalmique comprenant un beta-bloquant
EP1074545A4 (en) * 1998-04-23 2001-08-22 Hiroyoshi Hidaka ISOCHINOLINE SULPHONAMIDE DERIVATIVES AND MEDICINES CONTAINING IT AS AN ACTIVE INGREDIENT
JP4212149B2 (ja) * 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
US6673812B1 (en) 1998-08-17 2004-01-06 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
NZ510098A (en) * 1998-10-22 2003-09-26 Neurosearch As Substituted phenyl derivatives, pharmaceuticals thereof and their use as blockers of the chloride channel

Also Published As

Publication number Publication date
CY1108651T1 (el) 2014-04-09
EP1818059A1 (en) 2007-08-15
BRPI0519007A2 (pt) 2008-12-23
CA2585372A1 (en) 2006-06-29
KR101286813B1 (ko) 2013-07-17
AU2005320085B2 (en) 2010-07-29
EP1818059A4 (en) 2007-12-26
MX2007007614A (es) 2007-08-15
HK1113312A1 (zh) 2008-10-03
DK1818059T3 (da) 2009-03-16
NO20072187L (no) 2007-07-13
CN101087613A (zh) 2007-12-12
EA011085B1 (ru) 2008-12-30
TW200628160A (en) 2006-08-16
ATE415972T1 (de) 2008-12-15
JP4099201B2 (ja) 2008-06-11
SI1818059T1 (sl) 2009-04-30
ES2317338T3 (es) 2009-04-16
NZ555137A (en) 2009-10-30
WO2006068208A1 (ja) 2006-06-29
ZA200704874B (en) 2008-08-27
KR20070090897A (ko) 2007-09-06
PL1818059T3 (pl) 2009-05-29
AU2005320085A1 (en) 2006-06-29
PT1818059E (pt) 2008-12-31
EP1818059B1 (en) 2008-12-03
DE602005011476D1 (de) 2009-01-15
MY138811A (en) 2009-07-31
EA200701134A1 (ru) 2007-10-26
JPWO2006068208A1 (ja) 2008-06-12
CN101087613B (zh) 2010-08-18

Similar Documents

Publication Publication Date Title
NO20072187L (no) Preventivt eller terapeutisk middel for glaucom
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2006066103A3 (en) Ophthalmic implant for treatment of glaucoma
WO2002080811A3 (en) Glaucoma stent and methods thereof for glaucoma treatment
WO2003005941A3 (de) Insert zur behandlung des trockenen auges
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004069181A3 (en) Composition for the treatment of intraocular pressure
WO2007076367A3 (en) Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma
WO2007126364A8 (en) Use of antisecretory factors for treating intraocular hypertension
WO2006068829A9 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (lox) and lox-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2005027884A3 (en) Stabilized ocular solutions
WO2007127711A3 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
ZA200607988B (en) Statins for the treatment of ocular hypertension and glaucoma
MX2008015976A (es) Tratamiento topico para enfermedades de superficie ocular.
WO2004019874A3 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
EP1482922A4 (en) AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION FOR TREATING OR PREVENTING OCULAR DISORDERS
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
WO2003101379A3 (en) Pyranoindazoles and their use for the treatment of glaucoma
TW200806284A (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
WO2002060339A3 (en) Ophthalmic compositions for treating ocular hypertension
HK1075466A (zh) 调节、抑制或调控结缔组织生长因子(ctgf)的活性和/或表达的试剂
IL163938A0 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
WO2004087051A3 (en) Ophthalmic compositions for treating ocular hypertension

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees